Key Development
According to official ownership disclosure filings submitted to the Ho Chi Minh City Stock Exchange (HoSE), Mr. Kieu Huu – Chairman of the Board of Directors of Central Pharmaceutical Joint Stock Company VIDIPHA (HoSE: VDP) – has completely divested his entire holding of 1,652,917 VDP shares, representing 7.48% of the company’s charter capital.
The transaction was formally finalized on August 20, 2026, coinciding exactly with Mr. Kieu Huu’s 78th birthday (born August 20, 1948). Following the transaction, his equity ownership dropped to $0\%$, concluding his status as a major shareholder after leading the company for more than two decades.
Concurrent Divestment Wave Across Corporate Insiders and Affiliated Persons:
-
Chairman’s Daughter: Ms. Kieu Thuy Mai (daughter of Chairman Kieu Huu) divested her entire position of 1,377,944 shares (representing 6.24% of equity) between August 5 and August 20, 2026, reducing her stake to $0\%$. In aggregate, the Chairman and his daughter divested over 3.03 million shares (13.72% of charter capital).
-
Spouses of Board Members:
-
Ms. Dinh Thi Hoang Oanh (spouse of Board Member Pham Tuan Kiet) sold her entire stake of 2,549,520 shares (11.54% of equity), terminating her major shareholder status.
-
Ms. Nguyen Thi Anh Thuy (spouse of Board Member Tran Van Dat) completed the sale of 1,020,000 shares (4.61% of equity).
-
-
Aggregate Transaction Volume: Within the trading window from August 5 to August 20, 2026, the Chairman, his daughter, and spouses of two Board members liquidated nearly 6.6 million VDP shares, equivalent to approximately 29.87% of Vidipha’s total charter capital.
Why It Matters
-
Conclusion of a 23-Year Executive Tenure: Mr. Kieu Huu represents a foundational leadership figure in Vidipha’s corporate history, having served as Director of its state-owned predecessor (Central Pharmaceutical Technology Development Company) before becoming Chairman and CEO upon equitization in 2003, and continuing as Chairman from 2014 onward. Divesting his entire holding at age 78 signals a planned generational transition in financial ownership.
-
Indications of Strategic Shareholding Reorganization: The rapid transfer of nearly 30% of outstanding equity via matched orders and negotiated put-through transactions suggests the entry of new institutional investors or the consolidation of controlling blocks by strategic healthcare partners.
-
Positive Core Operations & EU-GMP CapEx Pipeline: The ownership transition occurs against a backdrop of stable financial performance:
-
First Half 2026 (H1 2026): Net revenue reached VND 429 billion, with net profit after tax rising approximately 16% YoY to VND 31 billion.
-
The company is executing a VND 128 billion capital expenditure plan to construct an EU-GMP certified Cephalosporin powder-for-injection manufacturing line.
-
Healthcare Insight Analysis
From the perspective of Healthcare Insight, the ownership restructuring at Vidipha on August 25, 2026, reflects Generational Ownership Transition & Pharma Capital Reallocation across Vietnam’s post-equitization pharmaceutical manufacturers.
This corporate transaction illustrates three key strategic dynamics:
-
Planned Retirement Liquidity for Founding Executives: At 78 years of age, complete equity divestment allows long-tenured executive leadership to monetize historical equity value and reallocate family assets, establishing a clear pathway for managerial succession at future General Meetings of Shareholders.
-
Coordinated Block Transactions for Institutional Ingestion: The synchronized sale of ~30% equity across leadership families indicates structured off-market distribution designed to introduce institutional capital rather than retail open-market selling.
-
Financing EU-GMP Quality Upgrades: To compete effectively in Group 1 and Group 2 hospital drug procurement tenders under current Ministry of Health bidding circulars, Vidipha’s VND 128B Cephalosporin EU-GMP expansion requires dedicated strategic backing with strong capital commitments.
Market Implications
-
Short-Term Share Price Adjustment for VDP (HoSE): VDP shares experienced downward pressure, closing down $4.3\%$ at $\text{VND } 33,500\text{ per share}$ on August 25, 2026, reflecting the large volume of traded shares.
-
Monitoring Inbound Major Shareholder Disclosures: Equity markets will monitor upcoming regulatory filings to identify the incoming institutional entities or domestic pharmaceutical conglomerates acquiring the ~30% equity block.
-
Execution of EU-GMP Cephalosporin Project: Upgrading sterile manufacturing capacity to EU-GMP standards remains the primary catalyst for Vidipha’s medium-term hospital (ETC) tender competitiveness.
Ownership Divestment Matrix: Vidipha Leadership Group (August 2026)
| Insider / Affiliated Person | Corporate Role & Affiliation | Divested Volume (Shares) | Equity Stake Sold | Post-Trade Ownership |
| Mr. Kieu Huu | Chairman of the Board | 1,652,917 shares | 7.48% | 0% (Ceased major shareholder) |
| Ms. Kieu Thuy Mai | Daughter of Board Chairman | 1,377,944 shares | 6.24% | 0% |
| Ms. Dinh Thi Hoang Oanh | Spouse of Board Member P. T. Kiet | 2,549,520 shares | 11.54% | 0% (Ceased major shareholder) |
| Ms. Nguyen Thi Anh Thuy | Spouse of Board Member T. V. Dat | 1,020,000 shares | 4.61% | 0% |
| Aggregate Group Total | Corporate Leadership Group | 6,599,381 shares | 29.87% | Divested ~30% equity |